Friday, 17 Jan 2020

You are here

Skyrizi Outduels Humira in Psoriasis

A head-to-head trial has shown that risankizumab was significantly superior to adalimumab in providing skin clearance (PASI90) in patients with moderate-to-severe plaque psoriasis, with no difference in safety signals between the two agents. 

Risankizumab (Skyrizi), an interleukin-23 (IL-23) inhibitor, was FDA approved for use in psoriasis in April 2019, becoming the the third IL-23 inhibitor (includes guselkumab [Tremfya] and tildrakizumab [Ilumya]) approved in the last year for plaque psoriasis.

The IMMvent trial was a phase 3, randomised, double-blind, active-comparator-controlled trial that enrolled 605 adults with moderate-to-severe chronic plaque psoriasis and randomized them to either risankizumab (RIS) (150 mg subcutaneously at weeks 0 and 4 ) or adalimumab (ADA) (80 mg subcutaneously at randomisation, then 40 mg at weeks 1, 3, 5, and every other week thereafter during the first 16-weeks of the trial (part A). For weeks 16–44 (part B), adalimumab intermediate responders were re-randomised 1:1 to continue 40 mg adalimumab or switch to 150 mg risankizumab.

Co-primary endpoints in part A were a 90% improvement from baseline (PASI 90) and a static Physician's Global Assessment (sPGA) score of 0 or 1 at week 16.

Nearly all of the RIS (98%) and ADA (96%)patients completed part A (first 16 weeks) of the study. 

At week 16, PASI 90 results were:

  • RIS - 72%
  • ADA - 47% (p<0·0001)

In part B, at week 44, the ADA intermediate responders, achieved a PASI 90 in 66% of RIS treated patients and 21% in those continuing ADA therapy (p<0·0001).

Risankizumab showed significantly greater efficacy than adalimumab in providing skin clearance in moderate-to-severe plaque psoriasis.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Taltz Shines in Non-Radiographic Axial Spondyloarthritis

Ixekizumab (IXE), an interleukin-17A (IL-17A) inhibitor, was recently approved for use in ankylosing spondylitis (also known as radiographic axial spondyloarthritis- axSpA). Lancet has published the results of the COAST-X study showing that ixekizumab was effective in patients with non-radiographic axial spondyloarthritis.

Best of 2019 - SEAM-PsA Study - Does Monotherapy MTX Win Despite Losing to Etanercept in Psoriatic Arthritis?

The SEAM-PsA study examined the efficacy of methotrexate monotherapy, etanercept monotherapy or the combination of MTX and ETN in psoriatic arthritis patients, and found that ETN monotherapy was equivalent to combination therapy - and that both were superior to MTX alone in clinical (ACR and MDA) and radiographic responses.

Best of 2019 - ACR/SPARTAN Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

The American College of Rheumatology (ACR), in partnership with the Spondylitis Association of America (SAA) and the Spondyloarthritis Research and Treatment Network (SPARTAN), released the 2019 Update of the Recommendations for the Treatment of Ankylosing Spondylitis (AS) and Nonradiographic Axial Spondyloarthritis (nr-axSpA).

Upadacitinib Effective in Ankylosing Spondylitis

Lancet reports that the selective JAK1 inhibitor, upadacitinib, was effective when given to patients with active ankylosing spondylitis.

Secukinumab Improves Enthesitis

Secukinumabs (SEC) effect on enthesitis in psoriatic arthritis (PsA) was studied in the FUTURE 2 and 3 studies and SEC was shown significantly reduced enthesitis by more than 65% within 14 week.